Clinical characteristics, treatment methods and prognoses of patients with oral squamous cell carcinoma in Japanese population: a single institution retrospective cohort study.


Journal

BMC geriatrics
ISSN: 1471-2318
Titre abrégé: BMC Geriatr
Pays: England
ID NLM: 100968548

Informations de publication

Date de publication:
20 11 2020
Historique:
received: 02 06 2020
accepted: 12 11 2020
entrez: 21 11 2020
pubmed: 22 11 2020
medline: 14 1 2021
Statut: epublish

Résumé

The status of oral cancer therapy in elderly patients in Japan, where ageing is rapidly progressing, may serve as a model for other countries with similar demographics. There is controversy over what kind of treatment should be applied and how aggressively it should be applied to very elderly patients who have exceeded the average life expectancy. Given that 85 years is approximately the overall Japanese life expectancy at birth, we considered a threshold of 85 years and hypothesized that the prognosis of oral squamous cell carcinoma (SCC) patients aged ≥85 years was not inferior to that of those < 85 years. The aim of the present study was to investigate the clinical characteristics, treatment methods, and prognoses of Japanese oral SCC patients aged ≥85 years. A retrospective cohort study was performed. The data of patients with primary oral SCC (n = 358) from 2005 to 2018 in our institute were extracted from electronic medical records. A total of 358 patients with oral SCC were divided into two groups (≥85 years group [n = 26] and < 85 years group [n = 332]) based on the age threshold of 85 years at the first visit. Kaplan-Meier survival analyses and Cox proportional hazard models were used to analyse overall survival (OS) and hazard ratios (HRs) according to age group, treatment, and TNM classification. There was no difference in the 5-year OS rate between the ≥85 years and < 85 years groups (80.8% vs. 82.2%, P = 0.359). This finding was the same in the operative (94.7% vs. 85.8%, P = 0.556) and non-operative (42.9% vs. 33.2%, P = 0.762) groups, indicating that age did not affect prognosis. Mortality was lower in the operative group than in the non-operative group (adjusted HR: 0.276, 95% CI: 0.156-0.489, P < 0.001), suggesting that surgery is a superior method. However, non-surgical treatment was selected at a higher rate in the ≥85 years group (26.9% vs. 11.1%, P = 0.028). This study suggests the prognosis of ≥85-year-old patients was not inferior to that of < 85-year-old patients. We recommend that surgery as the first choice treatment for ≥85-year-old patients with oral SCC who can tolerate surgery should be performed.

Sections du résumé

BACKGROUND
The status of oral cancer therapy in elderly patients in Japan, where ageing is rapidly progressing, may serve as a model for other countries with similar demographics. There is controversy over what kind of treatment should be applied and how aggressively it should be applied to very elderly patients who have exceeded the average life expectancy. Given that 85 years is approximately the overall Japanese life expectancy at birth, we considered a threshold of 85 years and hypothesized that the prognosis of oral squamous cell carcinoma (SCC) patients aged ≥85 years was not inferior to that of those < 85 years. The aim of the present study was to investigate the clinical characteristics, treatment methods, and prognoses of Japanese oral SCC patients aged ≥85 years.
METHODS
A retrospective cohort study was performed. The data of patients with primary oral SCC (n = 358) from 2005 to 2018 in our institute were extracted from electronic medical records. A total of 358 patients with oral SCC were divided into two groups (≥85 years group [n = 26] and < 85 years group [n = 332]) based on the age threshold of 85 years at the first visit. Kaplan-Meier survival analyses and Cox proportional hazard models were used to analyse overall survival (OS) and hazard ratios (HRs) according to age group, treatment, and TNM classification.
RESULTS
There was no difference in the 5-year OS rate between the ≥85 years and < 85 years groups (80.8% vs. 82.2%, P = 0.359). This finding was the same in the operative (94.7% vs. 85.8%, P = 0.556) and non-operative (42.9% vs. 33.2%, P = 0.762) groups, indicating that age did not affect prognosis. Mortality was lower in the operative group than in the non-operative group (adjusted HR: 0.276, 95% CI: 0.156-0.489, P < 0.001), suggesting that surgery is a superior method. However, non-surgical treatment was selected at a higher rate in the ≥85 years group (26.9% vs. 11.1%, P = 0.028).
CONCLUSIONS
This study suggests the prognosis of ≥85-year-old patients was not inferior to that of < 85-year-old patients. We recommend that surgery as the first choice treatment for ≥85-year-old patients with oral SCC who can tolerate surgery should be performed.

Identifiants

pubmed: 33218306
doi: 10.1186/s12877-020-01902-3
pii: 10.1186/s12877-020-01902-3
pmc: PMC7678127
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

487

Références

J Clin Oncol. 2009 Jun 10;27(17):2758-65
pubmed: 19403886
Lancet Oncol. 2017 May;18(5):e274-e283
pubmed: 28456589
CA Cancer J Clin. 1997 Jan-Feb;47(1):5-27
pubmed: 8996076
Am J Surg. 1982 Oct;144(4):449-51
pubmed: 7125075
Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):46-51
pubmed: 20395066
J Geriatr Oncol. 2017 Jan;8(1):50-55
pubmed: 27720129
J Clin Oncol. 2014 Aug 20;32(24):2595-603
pubmed: 25071125
Otolaryngol Head Neck Surg. 2015 May;152(5):796-802
pubmed: 25820590
Am J Otolaryngol. 2013 Nov-Dec;34(6):631-5
pubmed: 23954137
Cancer Manag Res. 2018 Oct 12;10:4523-4535
pubmed: 30349385
Head Neck. 2012 Aug;34(8):1147-52
pubmed: 22021098
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
J Clin Oncol. 2018 Aug 1;36(22):2326-2347
pubmed: 29782209
Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):758-766
pubmed: 28366574
Biomed Res Int. 2018 Jan 17;2018:3508795
pubmed: 29581971
Clin Oncol (R Coll Radiol). 2009 Mar;21(2):92-8
pubmed: 19059768

Auteurs

Chonji Fukumoto (C)

Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Shimo-Tsuga, Tochigi, 321-0293, Japan. chonji-f@dokkyomed.ac.jp.

Shouhei Ogisawa (S)

Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Shimo-Tsuga, Tochigi, 321-0293, Japan.

Masashi Tani (M)

Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Shimo-Tsuga, Tochigi, 321-0293, Japan.

Toshiki Hyodo (T)

Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Shimo-Tsuga, Tochigi, 321-0293, Japan.

Ryouta Kamimura (R)

Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Shimo-Tsuga, Tochigi, 321-0293, Japan.

Yuta Sawatani (Y)

Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Shimo-Tsuga, Tochigi, 321-0293, Japan.

Tomonori Hasegawa (T)

Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Shimo-Tsuga, Tochigi, 321-0293, Japan.

Yuske Komiyama (Y)

Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Shimo-Tsuga, Tochigi, 321-0293, Japan.
Section of Dentistry, Oral and Maxillofacial Surgery, Sano Kosei General Hospital, 1728 Horigome town, Sano city, Tochigi, 327-8511, Japan.

Atsushi Fujita (A)

Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Shimo-Tsuga, Tochigi, 321-0293, Japan.

Takahiro Wakui (T)

Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Shimo-Tsuga, Tochigi, 321-0293, Japan.

Yasuo Haruyama (Y)

Department of Public Health, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Shimo-Tsuga, Tochigi, 321-0293, Japan.

Gen Kobashi (G)

Department of Public Health, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Shimo-Tsuga, Tochigi, 321-0293, Japan.

Hitoshi Kawamata (H)

Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Shimo-Tsuga, Tochigi, 321-0293, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH